The Effect of Polysaccharide Peptide (PsP) on the Improvement of Low-Density Lipoprotein (LDL) Profile Levels in Active Smokers with Dyslipidemia
Year: 2026
Type: book-chapter
Study design: Clinical Trial
Abstract: Indonesia continues to have a substantial smoking burden, and tobacco exposure can worsen dyslipidemia through oxidative stress and inflammation.Polysaccharide peptide (PsP) from Ganoderma lucidum contains β-D-glucan and other bioactive constituents that may support lipid control.This study assessed the LDL-C response to PsP in active smokers with dyslipidemia.Twenty-eight male students aged 18-21 years participated in a pretest-posttest controlled experiment.The intervention group (n=14) received 500 mg PsP orally each day for 30 days; the control group (n=14) received no PsP.LDL-C was determined before and after the study period.Paired t-tests assessed change within groups, and independent t-tests compared the magnitude of change.LDL-C fell significantly after PsP administration (p<0.001),but remained unchanged in controls (p=0.875).The difference in change between groups was significant (p<0.001).PsP may act through β-D-glucan-related antioxidant, antiinflammatory, and lipid-regulating pathways.Thus, 30-day supplementation with 500 mg/day PsP was associated with lower LDL-C in young active smokers with dyslipidemia.Confirmation in larger, longer, and placebo-controlled studies is needed.
Institutions: University of Brawijaya, Udayana University
Language: English
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funder: Universitas Brawijaya
OpenAlex ID: W7205008367
